142 related articles for article (PubMed ID: 22157417)
1. Myelodysplasia and autoimmunity.
Giannouli S; Kanellopoulou T; Voulgarelis M
Curr Opin Rheumatol; 2012 Jan; 24(1):97-102. PubMed ID: 22157417
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive review of myelodysplastic syndrome patients with autoimmune diseases.
Giannouli S; Voulgarelis M
Expert Rev Clin Immunol; 2014 Dec; 10(12):1679-88. PubMed ID: 25308147
[TBL] [Abstract][Full Text] [Related]
3. Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts.
Voulgarelis M; Giannouli S; Ritis K; Tzioufas AG
Eur J Clin Invest; 2004 Oct; 34(10):690-700. PubMed ID: 15473894
[TBL] [Abstract][Full Text] [Related]
4. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.
Aggarwal S; van de Loosdrecht AA; Alhan C; Ossenkoppele GJ; Westers TM; Bontkes HJ
Br J Haematol; 2011 Jun; 153(5):568-81. PubMed ID: 21488861
[TBL] [Abstract][Full Text] [Related]
5. Low C3 levels is associated with neutropenia in a proportion of patients with myelodysplastic syndrome: retrospective analysis.
Kim KJ; Kwok SK; Park YJ; Kim WU; Cho CS
Int J Rheum Dis; 2012 Feb; 15(1):86-94. PubMed ID: 22324951
[TBL] [Abstract][Full Text] [Related]
6. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
7. [Myelodysplastic syndromes and autoimmunity].
Stalder G; Alberio L; Ribi C
Rev Med Suisse; 2015 Apr; 11(469):820-2, 824-5. PubMed ID: 26040163
[TBL] [Abstract][Full Text] [Related]
8. Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes.
Kiladjian JJ; Visentin G; Viey E; Chevret S; Eclache V; Stirnemann J; Bourhis JH; Chouaib S; Fenaux P; Caignard A
Haematologica; 2008 Mar; 93(3):381-9. PubMed ID: 18268282
[TBL] [Abstract][Full Text] [Related]
9. Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence?
Braun T; Fenaux P
Best Pract Res Clin Haematol; 2013 Dec; 26(4):327-36. PubMed ID: 24507810
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous manifestations in relation to immunologic parameters in a cohort of primary myelodysplastic syndrome patients.
Dalamaga M; Karmaniolas K; Matekovits A; Migdalis I; Papadavid E
J Eur Acad Dermatol Venereol; 2008 May; 22(5):543-8. PubMed ID: 18070024
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.
Kerkhoff N; Bontkes HJ; Westers TM; de Gruijl TD; Kordasti S; van de Loosdrecht AA
Immunotherapy; 2013 Jun; 5(6):621-37. PubMed ID: 23725285
[TBL] [Abstract][Full Text] [Related]
12. Immune alterations in untreated and treated myelodysplastic syndrome.
Mewawalla P; Dasanu CA
Expert Opin Drug Saf; 2011 May; 10(3):351-61. PubMed ID: 21417834
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic syndromes: the pediatric point of view.
Locatelli F; Zecca M; Pession A; Maserati E; De Stefano P; Severi F
Haematologica; 1995; 80(3):268-79. PubMed ID: 7672722
[TBL] [Abstract][Full Text] [Related]
14. Biology of myelodysplastic syndromes.
Yoshida Y
Int J Cell Cloning; 1987 Sep; 5(5):356-75. PubMed ID: 3305727
[TBL] [Abstract][Full Text] [Related]
15. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
[TBL] [Abstract][Full Text] [Related]
16. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
17. Myelodysplastic syndromes with monocytic component: hematologic and cytogenetic characterization.
Rigolin GM; Cuneo A; Roberti MG; Bardi A; Castoldi G
Haematologica; 1997; 82(1):25-30. PubMed ID: 9107078
[TBL] [Abstract][Full Text] [Related]
18. Progression of myelodysplasia to acute lymphoblastic leukaemia: implications for disease biology.
Disperati P; Ichim CV; Tkachuk D; Chun K; Schuh AC; Wells RA
Leuk Res; 2006 Feb; 30(2):233-9. PubMed ID: 16046234
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune diseases in myelodysplastic syndrome favors patients survival: A case control study and literature review.
Seguier J; Gelsi-Boyer V; Ebbo M; Hamidou Z; Charbonnier A; Bernit E; Durand JM; Harlé JR; Vey N; Schleinitz N
Autoimmun Rev; 2019 Jan; 18(1):36-42. PubMed ID: 30408583
[TBL] [Abstract][Full Text] [Related]
20. The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia.
Cermák J; Belicková M; Krejcová H; Michalová K; Zilovcová S; Zemanová Z; Brezinová J; Sieglová Z
Leuk Res; 2005 Apr; 29(4):371-9. PubMed ID: 15725470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
